Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma-Reference-Cited by-同舟云学术

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

Published:2019-03-19 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Khair Duaa O.,Bax Heather J.,Mele Silvia,Crescioli Silvia,Pellizzari Giulia,Khiabany Atousa,Nakamura Mano,Harris Robert J.,French Elise,Hoffmann Ricarda M.,Williams Iwan P.,Cheung Anthony,Thair Benjamin,Beales Charlie T.,Touizer Emma,Signell Adrian W.,Tasnova Nahrin L.,Spicer James F.,Josephs Debra H.,Geh Jenny L.,MacKenzie Ross Alastair,Healy Ciaran,Papa Sophie,Lacy Katie E.,Karagiannis Sophia N.

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference144 articles.

1. Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer;James;BMC Cancer.,2017

2. CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma;Dudley;Clin Cancer Res.,2010

3. Cytokines in cancer pathogenesis and cancer therapy;Dranoff;Nat Rev Cancer.,2004

4. Interferon alpha/beta enhances the cytotoxic response of MEK inhibition in melanoma;Litvin;Mol Cell.,2015

5. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies;Atkins;Clin Cancer Res.,1997

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the multifaceted effects of silymarin on melanoma: Focusing on the role of lipid-based nanocarriers;Journal of Drug Delivery Science and Technology;2024-09

2. Bifurcations of a cancer immunotherapy model explaining the transient delayed response and various other responses;Communications in Nonlinear Science and Numerical Simulation;2024-08

3. Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab;Pigment Cell & Melanoma Research;2024-07-03

4. Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study;European Journal of Cancer;2024-07

5. Immunotherapy in melanoma: advances, pitfalls, and future perspectives;Frontiers in Molecular Biosciences;2024-06-28